Hsbc Holdings PLC Takes Position in Oscar Health, Inc. $OSCR

Hsbc Holdings PLC bought a new position in Oscar Health, Inc. (NYSE:OSCR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 33,969 shares of the company’s stock, valued at approximately $486,000.

Several other hedge funds also recently made changes to their positions in the company. BIT Capital GmbH boosted its position in Oscar Health by 545.0% during the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock valued at $88,897,000 after buying an additional 5,227,152 shares during the period. Morgan Stanley increased its position in shares of Oscar Health by 42.8% in the fourth quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock valued at $97,918,000 after acquiring an additional 2,043,758 shares during the period. Thrive Capital Management LLC increased its position in shares of Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock valued at $85,258,000 after acquiring an additional 1,588,395 shares during the period. Marshall Wace LLP increased its position in shares of Oscar Health by 3,796.6% in the third quarter. Marshall Wace LLP now owns 1,137,839 shares of the company’s stock valued at $21,539,000 after acquiring an additional 1,108,638 shares during the period. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of Oscar Health by 11.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock valued at $132,461,000 after acquiring an additional 910,320 shares during the last quarter. 75.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on OSCR. Robert W. Baird increased their target price on shares of Oscar Health from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Wolfe Research started coverage on Oscar Health in a report on Tuesday, May 5th. They set a “peer perform” rating on the stock. UBS Group upped their price target on Oscar Health from $15.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded Oscar Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 14th. Finally, Weiss Ratings upgraded Oscar Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Oscar Health has a consensus rating of “Hold” and an average price target of $20.78.

Insiders Place Their Bets

In other Oscar Health news, insider Adam Mcananey sold 9,859 shares of Oscar Health stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $216,306.46. Following the sale, the insider directly owned 218,096 shares of the company’s stock, valued at approximately $4,785,026.24. The trade was a 4.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Janet Liang sold 12,475 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total value of $273,701.50. Following the transaction, the insider owned 259,057 shares in the company, valued at $5,683,710.58. This trade represents a 4.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 3,662,466 shares of company stock valued at $105,145,815 over the last ninety days. 22.64% of the stock is owned by corporate insiders.

Oscar Health Trading Down 5.7%

NYSE:OSCR opened at $28.86 on Friday. The company has a 50-day moving average price of $26.77 and a 200-day moving average price of $18.88. Oscar Health, Inc. has a 12 month low of $10.69 and a 12 month high of $33.10. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.70 billion, a price-to-earnings ratio of -48.91, a P/E/G ratio of 1.71 and a beta of 2.34.

Oscar Health (NYSE:OSCR) last announced its earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The firm had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. During the same quarter in the previous year, the firm posted $0.92 EPS. The company’s revenue for the quarter was up 52.6% compared to the same quarter last year. Equities analysts predict that Oscar Health, Inc. will post 0.59 EPS for the current year.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.